• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Phio Pharmaceuticals Corp.

    8/28/25 4:01:04 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email
    DEFA14A 1 phio_defa14a.htm ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
       
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
         
    ☐   Definitive Proxy Statement
       
    ☒   Definitive Additional Materials
       
    ☐   Soliciting Material under §240.14a-12

     

    PHIO PHARMACEUTICALS CORP.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required.
       
    ☐   Fee paid previously with preliminary materials.
       
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

       

     

     

    PHIO PHARMACEUTICALS CORP.

    411 SWEDELAND ROAD, SUITE 23-1080

    KING OF PRUSSIA, PA 19406

     

     

    SUPPLEMENT TO

    PROXY STATEMENT DATED JULY 30, 2025

    FOR THE ANNUAL MEETING OF STOCKHOLDERS OF

    PHIO PHARMACEUTICALS CORP.

     

    Dear Stockholders of Phio Pharmaceuticals Corp.:

     

    You previously received definitive proxy materials dated July 30, 2025 (the “Proxy Statement”) in connection with the Annual Meeting of Stockholders of Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), to be held on September 11, 2025 at 9:00 a.m. (Eastern Time), virtually at meetnow.global/MVQDAFW.

     

    Proposal No. 3 in the Proxy Statement is a proposal to approve an amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan (the “Plan”) to increase the number of shares of Common Stock available for issuance thereunder by 950,000. Following the filing and mailing of the Proxy Statement, the Company discovered a scrivener’s error in the aggregate maximum number of shares of Common Stock that will be reserved for issuance under the Plan if Proposal No. 3 is approved by the stockholders of the Company at the Annual Meeting. The purpose of this document (this “Proxy Supplement”) is to correct such scrivener’s error. You should read this Proxy Supplement together with the Proxy Statement. Capitalized terms used but not defined herein have the meanings given to them in the Proxy Statement.

     

    Clarification of Aggregate Maximum Number of Shares of Common Stock Reserved for Issuance under the Plan

     

    Rather than a total of 950,891 shares of Common Stock, which was the number reported in the Proxy Statement, the amendment and restatement of the Plan, if approved, will result in an aggregate of 1,023,017 shares of Common Stock reserved for issuance under the Plan, which is the sum of: (i) 950,000 shares added pursuant to Proposal No. 3; (ii) 71,000 shares of Common Stock subject to outstanding RSUs as of the Record Date; (iii) 1,126 shares of Common Stock subject to outstanding stock options as of the Record Date; and (iv) 891 shares of Common Stock that remained available for issuance under the Plan as of the Record Date. Accordingly, all references to “950,891” shares of Common Stock in the Proxy Statement, including Appendix A thereto, are hereby replaced with “1,023,017” shares of Common Stock.

     

    Except as set forth herein, all other information in the Proxy Statement remains unchanged. If you have previously submitted a proxy and you do not wish to make any changes, you do not need to do anything further.

     

    YOUR VOTE IS VERY IMPORTANT. PLEASE VOTE YOUR SHARES PROMPTLY.

     

     

     

     

       

     

    Get the next $PHIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Phio Pharmaceuticals Corp.

    DEFA14A - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/28/25 4:01:04 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Phio Pharmaceuticals Corp.

    424B3 - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/27/25 5:04:25 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Phio Pharmaceuticals Corp.

    EFFECT - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    8/25/25 12:15:29 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

    6/24/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

    5/1/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

    Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

    2/20/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Carson Lisa Cabott

    3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/18/25 4:30:56 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 5:00:01 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 4:59:45 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 5:00:01 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/11/25 4:59:45 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    6/10/25 4:43:57 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended June 30, 2025 and provided a business update.Recent Corporate UpdatesPH-762 Clinical ProgressPhio's ongoing Phase 1b dose escalation clinical trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratum

    8/14/25 4:15:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

    King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outstanding warrants to purchase up to an aggregate of 928,596 shares of common stock of the Company originally issued in December 2024 and January 2025, having exercise prices between $2.00 and $3.00 per share. Warrants to purchase 100,000 shares of common stock at the existing exercise price of $2.00 per share will be exercised at their existing exercise price of

    7/25/25 3:04:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

    Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that pathologic results are available for four of the five patients treated in the fourth cohort. A complete pathologic response (100% tumor clearance) has been reported for one patient with cutaneous squamous cell carcinoma (cSCC). One patient with metastatic Merkel cell carc

    7/25/25 12:36:00 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    6/5/25 7:35:43 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

    6/14/21 6:22:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    11/13/24 11:20:45 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/6/24 10:30:10 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

    SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

    2/8/23 6:07:04 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care